Recursion Pharmaceuticals Announced That, On September 28, 2023, Roche Exercised The Validated Small Molecule Option In A Single Area Of Oncology Under The Collaboration And License Agreement Dated December 5, 2021, Roche Will Pay An Option Fee - 8K
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals announced that Roche has exercised the validated small molecule option in a single area of oncology under their collaboration and license agreement. Roche will pay an option fee as per the agreement dated December 5, 2021.
October 02, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Recursion Pharmaceuticals' collaboration with Roche in oncology progresses with Roche exercising an option. This could potentially bring in additional revenue for Recursion.
Roche's decision to exercise the option in the collaboration agreement with Recursion Pharmaceuticals indicates a positive development in their partnership. This could potentially lead to additional revenue for Recursion, which may positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100